Wei Ying | Cell-Cell Communication | Best Researcher Award

Dr. Wei Ying | Cell-Cell Communication | Best Researcher Award

Dr. Wei Ying | University of California, San Diego | United States

Dr. Wei Ying is an Associate Professor in the Department of Medicine at the University of California, San Diego (UCSD). A leading scientist in immunometabolism, she has made pioneering contributions to the understanding of how immune cells, particularly macrophages, regulate metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Dr. Ying’s research bridges immunology and endocrinology, uncovering novel intercellular signaling pathways mediated by exosomes and miRNAs. With over 67 peer-reviewed publications and 6,000+ citations, she is widely recognized for her impactful research. She serves as co-corresponding author on several high-impact papers in Cell Metabolism, Science Immunology, and Nature Communications. Dr. Ying’s innovative work continues to shape therapeutic strategies targeting immune-metabolic diseases. In recognition of her outstanding achievements, she is a compelling nominee for the Best Researcher Award. Her leadership, mentorship, and continuous scientific productivity mark her as a standout in biomedical research.

Publication Profiles: 

Google Scholar
Orcid

Education:

Dr. Wei Ying earned her Ph.D. in Immunology and Endocrinology from Texas A&M University, under the mentorship of Drs. Fuller Bazer and Beiyan Zhou. During her Ph.D., she conducted breakthrough work on macrophage polarization and its effects on metabolic disorders, setting the foundation for her lifelong research focus. She received multiple academic honors during her doctoral studies, reflecting her scholarly excellence. Following her Ph.D., she pursued postdoctoral training at UC San Diego, mentored by the renowned Dr. Jerrold Olefsky. There, she expanded her expertise in diabetes and immunometabolism, focusing on novel signaling molecules like exosomal miRNAs in metabolic inflammation. Her educational path reflects a strong interdisciplinary background, integrating reproductive biology, immunology, and metabolic research. This robust academic training laid the groundwork for her current position as Associate Professor at UCSD, where she continues to lead cutting-edge research in metabolism and immune regulation.

Experience:

Dr. Ying’s research journey began as a Ph.D. student at Texas A&M University, where she studied immune-endocrine interactions. As a postdoctoral fellow at UC San Diego, she made pivotal discoveries regarding the role of macrophage-derived exosomal miRNAs in regulating systemic insulin sensitivity. She served as Assistant Professor at UCSD, establishing a successful independent lab investigating immune-metabolic crosstalk. She was promoted to Associate Professor, a testament to her scientific leadership and research impact. Over the years, she has mentored numerous trainees, contributed to 67+ publications, and led collaborative projects with top-tier labs. Her work frequently appears in prestigious journals like Cell Metabolism, Science Immunology, Hepatology, and Nature Communications. Her expertise spans immunology, metabolism, liver disease, and diabetes, and she continues to advance therapeutic research through mechanistic insights into macrophage function and intercellular communication.

Awards and Honors:

Dr. Wei Ying has been recognized with several prestigious awards throughout her career. Early in her academic journey, she received the Larry Ewing Memorial Trainee Travel Fund and the Interdisciplinary Faculty of Reproductive Biology Trainee Travel Award, highlighting her academic promise. She earned second place at Texas A&M University Student Research Week, acknowledging her impactful Ph.D. research. Beyond early-career accolades, her ongoing research excellence is reflected in multiple invited publications in top-tier journals and co-authorship in high-impact collaborative projects. With a cumulative citation count of over 6,000 and rising, her work has earned wide recognition in the fields of immunometabolism and diabetes research. As a co-corresponding and co-first author on many significant papers, she plays a central role in shaping the current landscape of metabolic research. Dr. Ying’s accolades underscore her qualifications for the Best Researcher Award.

Research Focus:

Dr. Ying’s research lies at the nexus of immunology and metabolism, focusing on how immune cells, particularly macrophages, regulate metabolic inflammation, insulin resistance, liver fibrosis, and β-cell function. Her work has unveiled how exosomal microRNAs, bacterial DNA, and iron metabolism contribute to disease progression in obesity and diabetes. She employs multi-disciplinary approaches—ranging from transcriptomics and in vivo mouse models to high-resolution imaging and CRISPR editing—to explore the molecular underpinnings of metabolic disorders. Notably, her studies on macrophage-derived exosomes have opened up therapeutic possibilities for improving insulin sensitivity and combating systemic inflammation. Her ongoing investigations also include the role of Kupffer cells in liver health, microbial DNA in inflammation, and ATF4 in T-cell function, demonstrating a robust expansion of research scope. Dr. Ying’s research continues to drive translational innovations, making her an influential figure in metabolic disease research and a strong candidate for the Best Researcher Award.

Publications Top Notes:

  1. ATF4 drives regulatory T cell functional specification in homeostasis and obesity – Science Immunology

  2. Host metabolic inflammation fueled by bacterial DNA – Trends in Endocrinology & Metabolism

  3. Restoring SRSF3 in Kupffer cells attenuates obesity-related insulin resistance – Hepatology

  4. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis – Cell Metabolism

  5. Accumulation of microbial DNAs promotes islet inflammation and β cell abnormalities – Nature Communications

  6. Immunosuppression of macrophages underlies the cardioprotective effects of Catestatin – Hypertension

  7. miR-690 from M2 macrophages improves insulin sensitivity in obese mice – Cell Metabolism

  8. CRIg+ macrophages prevent microbial DNA-induced tissue inflammation and insulin resistance – Gastroenterology

  9. Hepatocyte exosomes promote insulin sensitivity via miR-3075 – Nature Metabolism

  10. Expansion of islet-resident macrophages affects β cell function in obesity – Cell Metabolism

Conclusion:

In conclusion, Dr. Wei Ying is not only a prolific and highly cited researcher but also a scientific leader whose work has significantly advanced the understanding of immune-metabolic interactions in chronic disease. Her contributions are original, mechanistically insightful, and have meaningful implications for the treatment of metabolic diseases such as obesity, diabetes, and liver fibrosis. Her demonstrated ability to lead high-impact studies, publish consistently in elite journals, and maintain academic excellence through mentoring and innovation makes her highly deserving of the Best Researcher Award. While opportunities exist for expansion into clinical application and broader leadership roles, her trajectory strongly suggests continued excellence and influence in the years ahead. Dr. Ying exemplifies the qualities of a top-tier researcher and stands as a model for interdisciplinary biomedical science.

Tian Lan | Metabolic diseases | Best Researcher Award

Prof Tian Lan | Metabolic diseases | Best Researcher Award

Prof Tian Lan ,  Harbin Medical University , China

Prof. Tian Lan is a leading researcher in molecular pharmacology at Harbin Medical University, China. With over 20 completed and ongoing research projects, his work primarily addresses metabolic diseases such as fatty liver, diabetes, and cardiovascular disorders. Prof. Lan is widely recognized for his innovative approaches to drug development, which aim to improve patient outcomes through novel pharmacological targets. He has published over 60 articles in prestigious journals, contributed to multiple patents, and collaborated with esteemed institutions like UC San Diego. His dedication to advancing medical knowledge and practice has garnered him significant citations, reflecting his impactful contributions to the field. Prof. Lan’s work embodies a blend of rigorous scientific research and practical applications, positioning him as a prominent figure in the study of metabolic diseases.

Publication profile

Scopus

Strengths for the Award

Prof. Tian Lan demonstrates exceptional expertise in molecular pharmacology, particularly in the realm of metabolic diseases. His prolific output includes over 60 publications in high-impact journals, a citation index exceeding 4000, and numerous ongoing and completed research projects (20+). His innovative research has led to the identification of new pharmacological targets and the development of novel therapeutic strategies, particularly for conditions like fatty liver disease and diabetes. Notable contributions include significant findings on GSTM2 and its role in metabolic disorders, as well as advancements in understanding cordycepin’s mechanisms. His collaborative work with prestigious institutions like UC San Diego showcases his ability to foster partnerships that enhance research impact.

Areas for Improvement

While Prof. Lan has made significant strides in research, enhancing public outreach and engagement with the broader community could amplify the impact of his findings. Increased participation in conferences and workshops to disseminate knowledge more widely could also benefit both his research visibility and collaborations.

Education 

Prof. Tian Lan earned his PhD in Molecular Pharmacology from a prestigious institution, where he developed a strong foundation in pharmacological research and therapeutic strategies. His education was characterized by a rigorous curriculum that combined both theoretical knowledge and practical laboratory skills. He pursued postdoctoral studies that further enhanced his expertise in metabolic diseases, focusing on the interplay between pharmacology and cellular mechanisms. His academic journey included extensive training in advanced research methodologies, allowing him to investigate complex biological systems and their responses to pharmacological interventions. Prof. Lan’s commitment to continuous learning has led him to engage in various workshops and conferences, where he has remained abreast of the latest developments in pharmacology and related fields. This educational background has been instrumental in shaping his research focus and methodology, ultimately contributing to his success as a researcher and educator.

Experience 

Prof. Tian Lan has extensive experience in both academic and research environments, contributing significantly to the field of molecular pharmacology. He has led numerous research projects at Harbin Medical University, focusing on drug development for metabolic diseases. With over 60 publications in high-impact journals, his research has been widely cited, reflecting his influence in the scientific community. Prof. Lan has also engaged in consultancy projects, collaborating with industry partners to translate research findings into practical applications. His editorial appointments in reputable journals further underscore his expertise and leadership within the field. Additionally, he has fostered collaborations with renowned institutions like the Chinese University of Hong Kong and UC San Diego, enhancing the scope and impact of his work. His participation in professional organizations, such as AASLD and ADA, highlights his commitment to ongoing professional development and contribution to advancing research in metabolic diseases.

Research Focus

Prof. Tian Lan’s research is centered on the molecular pharmacology of metabolic diseases, particularly focusing on fatty liver disease, diabetes, gout, and cardiovascular disorders. His innovative studies aim to uncover new pharmacological targets and develop novel therapeutic strategies that address these pressing health issues. By exploring the mechanisms behind metabolic dysfunction, Prof. Lan has made significant contributions to understanding how various pathways, such as the MAPK and ASK1 signaling pathways, can be modulated to improve disease outcomes. His work with glutathione S-transferase Mu2 (GSTM2) and cordycepin has revealed potential therapeutic targets that mitigate metabolic disorders and inflammatory damage. Furthermore, his research on traditional Chinese medicine and its integration with Western pharmacology showcases his commitment to a holistic approach in treatment. Overall, Prof. Lan’s focus on molecular mechanisms and drug development positions him at the forefront of advancing therapeutic options for metabolic diseases.

Publications Top Notes

  1. Qi Nan agarwood restores podocyte autophagy in diabetic kidney disease by targeting EGFR signaling pathway 📄
  2. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies 📄
  3. Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies 📄
  4. Fufang Zhenzhu Tiaozhi polysaccharides ameliorates high-fat diet-induced non-alcoholic steatohepatitis and intestinal flora disorders in mice 📄
  5. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action 📄
  6. Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway 📄
  7. Arbutin ameliorates liver fibrosis in mice by inhibiting macrophage recruitment and regulating the Akt/NF-κB and Smad signaling pathways 📄
  8. FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis 📄
  9. Glaucocalyxin A attenuates carbon tetrachloride-induced liver fibrosis and improves the associated gut microbiota imbalance 📄

Conclusion

Prof. Tian Lan’s robust research portfolio, significant contributions to pharmacology, and commitment to advancing our understanding of metabolic diseases position him as a leading candidate for the Best Researcher Award. His work not only contributes to academic knowledge but also holds the potential for substantial clinical applications, ultimately improving patient outcomes in metabolic health. Recognizing his achievements with this award would validate his impact on the field and inspire further innovation in research.